Figure 1 | Scientific Reports

Figure 1

From: A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody

Figure 1

HYPERLINK "sps:id::fig1||locator::gr1||MediaObject::0"BLI assay to determine the affinities of ZGGS15 to human LAG-3 and human TIGIT. (A) BLI assay probes containing ZGGS15 were incubated with serial dilutions of human LAG-3 to determine binding affinity of 3.05 nM. (B) BLI assay probes containing ZGGS15 were loaded into serial dilutions of human TIGIT to determine a binding affinity of 2.65 nM. (C) Simultaneous binding of ZGGS15 to human LAG-3 and human TIGIT. Sensor binding traces are shown above in (C), and the binding pattern for each channel is listed below in (C). On Channel 1(red trace), the TIGIT-loaded probe associates with ZGGS15 in the “Bind #1” step. In the “Bind #2” step, the binding of human TIGIT to the ZGGS15-LAG-3 complex can be observed.

Back to article page